Investigating how IL-15 affects skin cancer progression in patients with Cutaneous T-cell Lymphoma.
Official title: The Role of IL-15 in Cutaneous T-cell Lymphoma Progression
Funded at Thomas Jefferson University · NIH-10891650 · Data updated 2026-11-12
This study is looking at how a protein called IL-15 affects the growth and movement of skin cancer cells in people with Cutaneous T-cell Lymphoma, using a special mouse model to find new ways to treat this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 20, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $339,008 |
| NIH project number | 5R01CA266592-02 |
| Project ID | NIH-10891650 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Cutaneous T-cell Lymphoma who are experiencing progressive skin symptoms.
✕Less likely to help
Patients with other types of skin cancers or those without a diagnosis of Cutaneous T-cell Lymphoma may not benefit from this research.
What this research studies
This research focuses on Cutaneous T-cell Lymphoma (CTCL), a skin cancer characterized by the accumulation of abnormal T lymphocytes. The study aims to understand how a protein called interleukin-15 (IL-15) contributes to the progression of this disease. Researchers will use a special mouse model that mimics human CTCL to explore how IL-15 influences the behavior of cancerous T-cells and their movement to the skin. By uncovering these mechanisms, the research hopes to identify new treatment strategies for managing CTCL.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve the quality of life for patients with Cutaneous T-cell Lymphoma.
How similar studies have gone: Previous research has shown promising results in understanding the role of IL-15 in other cancers, suggesting potential for success in this area as well.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Mishra, Anjali — Thomas Jefferson University
- Study coordinator: Mishra, Anjali
Related research
Other NIH-funded projects on the same topics.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
-
Understanding how IL-15 affects T-cell lymphoma in the skin
This research explores how a specific signal, called IL-15, helps T-cell lymphoma cells move to and grow in the skin, aiming to find new ways to help patients with this condition.
-
New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma
This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.
-
Investigating how Staphylococcus aureus affects skin cancer development
This study is looking at how a common skin bacteria called Staphylococcus aureus might affect the growth of Cutaneous T-cell lymphomas (CTCL), a type of skin cancer, by examining the bacteria found on patients' skin to find new ways to understand and treat the disease.
-
Understanding how gene regulation affects cutaneous T cell lymphoma
This study is looking at how changes in DNA can affect a type of skin cancer called cutaneous T cell lymphoma, especially a severe form known as Sezary syndrome, to help find better ways to diagnose and treat it, and patients can help us learn more about how these changes might impact their treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.